Complix NV
Technologiepark 94
9052 Zwijnaarde
BE
Complix NV
Foundation date
23/06/2008
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Cardiovascular
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
- #Neoplasms / cancer / oncology
Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.
Upcoming events
All events-
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté -
0204 '25
The Franco-Belgian Agrifood Summit
Event by: CCI France - Belgique
Latest news
More news-
Bio Base Europe Pilot Plant successfully commissions a 75,000 L fermenter, demonstrating Vivici’s Vivitein™ BLG technology in industrial-scale precision fermentation
9 hours ago
Read more
-
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
1 day ago
Read more
-
ExeVir Announces Michael Garrett as New Chief Executive Officer
Tuesday November 19th 2024
Read more
Jobs
More jobs-
-
-
20/11/24
Antwerp
Postdoc position in the Laboratory for Gut-Immune-Brain Axis Research
Permanent
VIB
More info?
Ellen Telleir
Communication Coordinator